nach oben

World Journal of Urology

Erschienen in:

08.09.2018 | Original Article

Alvimopan usage increasing following radical cystectomy

verfasst von: Joshua D. Belle, Aydin Pooli, Dimitry Oleynikov, Christopher M. Deibert

Erschienen in: World Journal of Urology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Alvimopan (Entereg), a peripherally acting opioid receptor antagonist, is effective in reducing the rate of postoperative ileus and length of hospital stay in patients undergoing colorectal surgery, and is now approved for use after radical cystectomy (RC). Using data from Vizient (formerly University Health System Consortium), we assessed the utilization of alvimopan and its effect on perioperative factors after RC.

Methods

The Vizient database, contributed to by over 200 US academic hospitals, was evaluated from 2014 to 2016. Patients who had undergone radical cystectomy were included. Alvimopan exposure and postoperative outcomes were collected.

Results

7472 patients underwent cystectomy in the 3 years examined, with 3391 (45.4%) patients receiving alvimopan over this time period. The use of alvimopan increased from 35 to 59%. The receipt of alvimopan was associated with a decrease in perioperative morbidity (10.53% vs 19.23%, p = 0.027).

Conclusion

This study, the largest to examine the real-world utilization of alvimopan since FDA approval for RC, shows that alvimopan utilization has increased substantially and is associated with reduced perioperative morbidity in patients undergoing cystectomy.

Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW, Donat SM (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55(1):164–174. https://doi.org/10.1016/j.eururo.2008.07.031 CrossRefPubMed

Novotny V, Hakenberg OW, Wiessner D, Heberling U, Litz RJ, Oehlschlaeger S, Wirth MP (2007) Perioperative complications of radical cystectomy in a contemporary series. Eur Urol 51(2):397–402. https://doi.org/10.1016/j.eururo.2006.06.014 CrossRefPubMed

Boström PJ, Kössi J, Laato M, Nurmi M (2009) Risk factors for mortality and morbidity related to radical cystectomy. BJU Int 103(2):191–196. https://doi.org/10.1111/j.1464-410X.2008.07889.x CrossRefPubMed

Maffezzini M, Campodonico F, Canepa G, Gerbi G, Parodi D (2008) Current perioperative management of radical cystectomy with intestinal urinary reconstruction for muscle-invasive bladder cancer and reduction of the incidence of postoperative ileus. Surg Oncol 17(1):41–48. https://doi.org/10.1016/j.suronc.2007.09.003 CrossRefPubMed

van Hemelrijck M, Thorstenson A, Smith P, Adolfsson J, Akre O (2013) Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients. BJU Int 112(8):1113–1120. https://doi.org/10.1111/bju.12239 CrossRefPubMedPubMedCentral

Holzer P (2009) Opioid receptors in the gastrointestinal tract. Regul Pept 155(1–3):11–17. https://doi.org/10.1016/j.regpep.2009.03.012 CrossRefPubMedPubMedCentral

Kumar L, Barker C, Emmanuel A (2014) Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract 2014:141737. https://doi.org/10.1155/2014/141737 CrossRefPubMedPubMedCentral

Anantharamu T, Sharma S, Gupta AK, Dahiya N, Singh Brashier DB, Sharma AK (2015) Naloxegol: first oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother 6(3):188–192. https://doi.org/10.4103/0976-500x.162015 CrossRefPubMedPubMedCentral

Lavine G (2008) New drug to restore bowel function approved under new FDA rules. Am J Health Syst Pharm 65(13):1204. https://doi.org/10.2146/news080052 CrossRefPubMed

10.

Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M (2014) Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol 66(2):265–272. https://doi.org/10.1016/j.eururo.2014.02.036 CrossRefPubMed

11.

Daneshmand S, Ahmadi H, Schuckman AK, Mitra AP, Cai J, Miranda G, Djaladat H (2014) Enhanced recovery protocol after radical cystectomy for bladder cancer. J Urol 192(1):50–55. https://doi.org/10.1016/j.juro.2014.01.097 CrossRefPubMed

12.

Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O’Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM (2014) Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol 191(6):1721–1727. https://doi.org/10.1016/j.juro.2013.12.015 CrossRefPubMed

13.

Ehlers AP, Simianu VV, Bastawrous AL, Billingham RP, Davidson GH, Fichera A, Florence MG, Menon R, Thirlby RC, Flum DR, Farjah F (2016) Alvimopan use, outcomes, and costs: a report from the surgical care and outcomes assessment program comparative effectiveness research translation network collaborative. J Am Coll Surg 222(5):870–877. https://doi.org/10.1016/j.jamcollsurg.2016.01.051 CrossRefPubMedPubMedCentral

14.

Siemens W, Gaertner J, Becker G (2015) Advances in pharmacotherapy for opioid-induced constipation—a systematic review. Expert Opin Pharmacother 16(4):515–532. https://doi.org/10.1517/14656566.2015.995625 CrossRefPubMed

15.

Becker G, Blum HE (2009) Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 373(9670):1198–1206. https://doi.org/10.1016/s0140-6736(09)60139-2 (London, England) CrossRefPubMed

16.

Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, Du W, Schmidt WK, Wallin BA (2005) Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 48(6):1114–1125. https://doi.org/10.1007/s10350-005-0035-7 (discussion 1125–1116; author reply 1127–1119) CrossRefPubMed

17.

Adam MA, Lee LM, Kim J, Shenoi M, Mallipeddi M, Aziz H, Stinnett S, Sun Z, Mantyh CR, Thacker JK (2016) Alvimopan provides additional improvement in outcomes and cost savings in enhanced recovery colorectal surgery. Ann Surg 264(1):141–146. https://doi.org/10.1097/sla.0000000000001428 CrossRefPubMed

18.

Brady JT, Dosokey EM, Crawshaw BP, Steele SR, Delaney CP (2015) The use of alvimopan for postoperative ileus in small and large bowel resections. Expert Rev Gastroenterol Hepatol 9(11):1351–1358. https://doi.org/10.1586/17474124.2015.1095637 CrossRefPubMed

19.

Drake TM, Ward AE (2016) Pharmacological management to prevent ileus in major abdominal surgery: a systematic review and meta-analysis. J Gastrointest Surg 20(6):1253–1264. https://doi.org/10.1007/s11605-016-3140-0 CrossRefPubMed

20.

Nguyen DL, Maithel S, Nguyen ET, Bechtold ML (2015) Does alvimopan enhance return of bowel function in laparoscopic gastrointestinal surgery? A meta-analysis. Ann Gastroenterol 28(4):475–480PubMedPubMedCentral

21.

Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM (2017) Treatment of non-metastatic muscle-invasive bladder cancer: aUA/ASCO/ASTRO/SUO Guideline. J Urol 198(3):552–559. https://doi.org/10.1016/j.juro.2017.04.086 CrossRefPubMedPubMedCentral

22.

Baack Kukreja JE, Messing EM, Shah JB (2016) Are we doing “better”? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists. Urol Oncol 34(3):120.e117–120.e121. https://doi.org/10.1016/j.urolonc.2015.10.002 CrossRef

23.

Konety BR, Allareddy V, Herr H (2006) Complications after radical cystectomy: analysis of population-based data. Urology 68(1):58–64. https://doi.org/10.1016/j.urology.2006.01.051 CrossRefPubMed

24.

Quek ML, Stein JP, Daneshmand S, Miranda G, Thangathurai D, Roffey P, Skinner EC, Lieskovsky G, Skinner DG (2006) A critical analysis of perioperative mortality from radical cystectomy. J Urol 175(3):886–890. https://doi.org/10.1016/S0022-5347(05)00421-0 CrossRefPubMed

25.

Cui Y, Chen H, Qi L, Zu X, Li Y (2016) Effect of alvimopan on accelerates gastrointestinal recovery after radical cystectomy: a systematic review and meta-analysis. Int J Surg 25:1–6. https://doi.org/10.1016/j.ijsu.2015.11.013 (London, England) CrossRefPubMed

26.

Vora A, Marchalik D, Nissim H, Kowalczyk K, Bandi G, McGeagh K, Lynch J, Venkatesan K, Ghasemian R, Hwang J, Hwang MV (2014) Multi-institutional outcomes and cost effectiveness of using alvimopan to lower gastrointestinal morbidity after cystectomy and urinary diversion. Can J Urol 21(2):7222–7227PubMed

27.

Vora AA, Harbin A, Rayson R, Christiansen K, Ghasemian R, Hwang J, Verghese M (2012) Alvimopan provides rapid gastrointestinal recovery without nasogastric tube decompression after radical cystectomy and urinary diversion. Can J Urol 19(3):6293–6298PubMed

28.

Hilton WM, Lotan Y, Parekh DJ, Basler JW, Svatek RS (2013) Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis. BJU Int 111(7):1054–1060. https://doi.org/10.1111/j.1464-410X.2012.11499.x CrossRefPubMed

Titel: Alvimopan usage increasing following radical cystectomy
verfasst von: Joshua D. Belle
Aydin Pooli
Dimitry Oleynikov
Christopher M. Deibert
Publikationsdatum: 08.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2476-3

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Alvimopan usage increasing following radical cystectomy

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2019

Optimizing male fertility: oxidative stress and the use of antioxidants

The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer

SIU Newsletter - June 2019

Male CP/CPPS: where do we stand?

Urinary neutrophil gelatinase-associated lipocalin as a biomarker to monitor renal function in patients with obstructive ureteral calculi

Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie